- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01630148
Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries
Bemiparin as a Thromboprophylaxis After Benign Gynaecological Surgeries:A Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Deep vein thrombosis (DVT) and pulmonary embolism (PE), also referred to as venous thromboembolic events (VTE), are two major complications after gynaecological surgeries that can result in significant morbidity and mortality. The incidence of VTE after gynaecologic surgery varies depending on the method used for diagnosis. The rate of clinical DVT is estimated to be 3% after gynaecological surgery if no thromboprophylaxis was used. The rate of VTE assumed to decrease to 0.4% if Low molecular weight heparin was used as a thromboprophylaxis.
According to our knowledge there are no published researches on the effect of the new second generation Low molecular Weight Heparin Bemiparin as a thromboprophylaxis after benign gynaecological surgery in comparison to a control group.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kurdistan region
-
Erbil city, Kurdistan region, Iraq, 383-65
- Hawler Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- female undergoing Benign gynecological surgeries.
- Having moderate,high and very high risk factors for venous thromboembolism.
- No contraindications for the use of Heparin.
Exclusion Criteria:
- Having mild risk factors for thromboembolism.
- Active vaginal bleeding.
- Thrombocytopaenia.
- any patient who is already on anticoagulant.
- Sever renal or Liver diseases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Bemiparin
group one will be women who are risky for venous thromboembolic diseases after benign gynaecological surgeries, each will receive Bemiparin
|
Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
Other Names:
|
NO_INTERVENTION: control group
women will undergo benign gynaecological surgeries and are risky for venous thrombosis, they will not receive any intervention.
The patients will be followed up to 30 days after surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evidences of clinical thromboembolic disease after gynaecological surgeries
Time Frame: within the first 30 days after surgery the first 30 days
|
to determine the efficacy of the new second generation LMWH in prevention Deep vein thrombosis and pulmonary embolism after gynaecological surgeries
|
within the first 30 days after surgery the first 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
to determine the side effects of Bemiparin injection
Time Frame: after receiving the injections and up to 30 days after surgery
|
To determine the safety of Bemiparin after gynaecological surgeries including bruising or pain at site of injection,itching,allergic skin reactions,urticaria, bleeding,
|
after receiving the injections and up to 30 days after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shahla K. Alalaf, M.D, Hawler Medical University
- Study Chair: Ariana K. Jawad, C.A.B.OG, Hawler Ministry of Health
- Study Chair: Rojan K. Jawad, Diploma, Hawler Medical University
- Study Chair: Mahabad S. Ali, Diploma, Hawler Ministry of Health
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HMU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Embolism
-
Boston Scientific CorporationEKOS CorporationCompletedPulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary EmbolismUnited States
-
Inari MedicalCompletedPulmonary Embolism | Submassive Pulmonary Embolism | Acute Pulmonary Embolism | Massive Pulmonary EmbolismUnited States
-
Hospital San Carlos, MadridAsociación de Cardiología Intervencionista de la Sociedad Española de CardiologíaRecruitingPulmonary Embolism | Pulmonary Embolism and Thrombosis | Pulmonary Thromboembolisms | Pulmonary Embolism Acute | Pulmonary Embolism Acute MassiveSpain
-
University of California, Los AngelesEnrolling by invitationPulmonary Disease | Pulmonary Embolism | Pulmonary Embolus/Emboli | Pulmonary Embolism and Thrombosis | Pulmonary Embolism Subacute Massive | Pulmonary Embolism Acute MassiveUnited States
-
Bristol-Myers SquibbCompletedPulmonary Embolism (PE) | Pulmonary ThromboembolismUnited Kingdom
-
Inari MedicalActive, not recruitingPE - Pulmonary Embolism | PE - Pulmonary ThromboembolismUnited States, Spain, Belgium, Germany, France, Switzerland, Netherlands, United Kingdom, Austria
-
GlaxoSmithKlineCompleted
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedPulmonary Hypertension | Pulmonary ThromboembolismsSpain
-
Victor Tapson, MDBristol-Myers SquibbTerminatedPulmonary Embolism | Right Ventricular Dysfunction | Right Ventricular Failure | Pulmonary Embolism With Acute Cor Pulmonale | Pulmonary Embolism With Pulmonary Infarction | Pulmonary Embolism Subacute MassiveUnited States
-
Imperative Care, Inc.RecruitingCardiovascular Diseases | Vascular Diseases | Embolism | Thrombosis | Thromboembolism | Acute Pulmonary Embolism | Thrombus; Embolism | Emboli, PulmonaryUnited States
Clinical Trials on Bemiparin
-
Rovi Pharmaceuticals LaboratoriesCompleted
-
Clinica Universidad de Navarra, Universidad de...Unknown
-
Rovi Pharmaceuticals LaboratoriesCompletedRenal InsufficiencySpain
-
Fundación Renal Iñigo Alvarez De ToledoInfociencia S.LCompleted
-
American University of Beirut Medical CenterCompleted
-
Hawler Medical UniversityRecruiting
-
Clinica Universidad de Navarra, Universidad de...Terminated
-
Instituto de Investigación Marqués de ValdecillaUnknown
-
Clinica Universidad de Navarra, Universidad de...Laboratorio farmacéutico ROVITerminatedCancer | ThrombosisSpain, Romania
-
Rovi Pharmaceuticals LaboratoriesCompletedCancer | Venous ThromboembolismSpain, Portugal, Romania, Russian Federation